<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02772198</url>
  </required_header>
  <id_info>
    <org_study_id>SHEBA-15-2076-AT-CTIL</org_study_id>
    <nct_id>NCT02772198</nct_id>
  </id_info>
  <brief_title>T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies</brief_title>
  <official_title>A Phase 1 / 2 Single Arm Study of T-cells Expressing Anti-CD19 Chimeric Antigen Receptor in Pediatric and Young Adult Patients With B-cell Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sheba Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sheba Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 1 / 2 study will evaluate the response of B-cell malignancies expressing CD19 to&#xD;
      autologous T cells transduced with a second generation anti-CD19 chimeric antigen receptor in&#xD;
      children and young adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Autologous T cells transduced with chimeric antigen receptors (CAR) that recognize the CD19&#xD;
      antigen (CD19-CAR T cells) have been used in multiple clinical trials at several institutions&#xD;
      worldwide. We established an in-house manufacturing process for CD19-CAR T cells with a CD28&#xD;
      (cluster of differentiation 28) costimulatory domain.&#xD;
&#xD;
      Primary Objectives:&#xD;
&#xD;
        1. To study the safety of administration of CAR T cell at the Sheba Medical Center&#xD;
&#xD;
        2. To determine the feasibility and efficacy of administering anti-CD19-CAR T cells in&#xD;
           children and young adults with B cell malignancies.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        1. To study in vivo and in vitro behavior of CAR T cell in patients, including persistence,&#xD;
           expansion, cytotoxic potential and exhaustion.&#xD;
&#xD;
        2. To study the cytokine milieu in CAR treated patients.&#xD;
&#xD;
      Eligibility Patients 1-50 years of age, with a CD19-expressing B-cell malignancy that has&#xD;
      recurred after, or not responded to, one or more standard chemotherapy-containing regimens.&#xD;
&#xD;
      Design Peripheral blood mononuclear cells (PBMCs)will be obtained by leukapheresis. Anti-CD19&#xD;
      CAR T cells will be manufactured from fresh autologous PBMCs. PBMC will be cultured in the&#xD;
      presence of anti-CD3 (cluster of differentiation 3) antibody and interleukin-2 followed by&#xD;
      retroviral vector supernatant containing the anti-CD19 CAR. Total culture time is between&#xD;
      7-10 days. Patients will receive lymphodepleting chemotherapy composed of cyclophosphamide&#xD;
      and fludarabine prior to cell infusion, and on day 0 will receive one million CAR T cells per&#xD;
      kilogram. Patients will be monitored for toxicity including cytokine release syndrome,&#xD;
      hematologic toxicities and B-cell aplasia; for response of their underlying malignancy; and&#xD;
      for CAR-T cell persistence in the blood, marrow and cerebral spinal fluid (CSF).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 2016</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment related adverse events as assessed by CTCAE v4.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate</measure>
    <time_frame>28 days</time_frame>
    <description>Overall response rate = complete response (CR) + partial response (PR) + complete response with incomplete count recovery (CRi) in leukemia patients; Assessment using bone marrow evaluation for patients with leukemia, and imaging (CT / PET CT) for patients with lymphoma</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Feasibility of CD19 CAR T cell production as defined by number of products successfully meeting release criteria</measure>
    <time_frame>12 days</time_frame>
    <description>For each participant, the feasibility of generating sufficient autologous CAR T cells within 12 days will be evaluated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CAR T cell persistence as measured by enumeration of CAR T cells in the blood and bone marrow of participants</measure>
    <time_frame>1 year</time_frame>
    <description>Enumeration of CAR T cells in the blood and bone marrow of participants</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>T cell activity and exhaustion profile as measured by flow cytometry</measure>
    <time_frame>3 months</time_frame>
    <description>Assessment of T cells from peripheral blood by flow cytometry for expression of activation and exhaustion markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine levels in the peripheral blood of the patients</measure>
    <time_frame>30 days</time_frame>
    <description>Measurement of cytokines in the blood of participants following CAR T cell administration</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Lymphoblastic Leukemia, B-precursor</condition>
  <condition>Non-Hodgkin Lymphoma, B-cell</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be treated on this single arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CD19 CAR T cells</intervention_name>
    <description>Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19</description>
    <arm_group_label>Single Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with relapsed or refractory B-cell malignancy&#xD;
&#xD;
          -  Age 1-50 years&#xD;
&#xD;
          -  CD19 expression shown by flow cytometry or immunohistochemistry on at least 70% of&#xD;
             leukemic blasts / lymphoma cells&#xD;
&#xD;
          -  Adequate CD3 count (above 250 CD3+ cells per microliter blood)&#xD;
&#xD;
          -  Clinical performance status: Patients &gt; 10 years of age: Karnofsky ≥ 50%; Patients ≤&#xD;
             10 years of age: Lansky scale ≥ 50%. Exception for neurologic symptoms (e.g.&#xD;
             paralysis) that are explained by the malignancy.&#xD;
&#xD;
          -  Females of child-bearing potential must have a negative pregnancy test&#xD;
&#xD;
          -  Cardiac function: Left ventricular ejection fraction &gt;45% or shortening fraction &gt;28%&#xD;
&#xD;
          -  For patients following allogeneic bone marrow transplantation - at least 100 days post&#xD;
             BMT with no signs or symptoms of active graft-versus-host disease.&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  Hyperleukocytosis (WBC&gt;50,000) or rapidly progressive disease&#xD;
&#xD;
          -  Pregnant or breast-feeding females&#xD;
&#xD;
          -  Hepatic dysfunction, defined as bilirubin &gt; x2 upper normal limit (except when&#xD;
             explained by hemolysis or Gilbert) or serum glutamate oxaloacetate transaminase &gt; x25&#xD;
             upper normal limit.&#xD;
&#xD;
          -  Hepatitis B, Hepatitis C or HIV infection.&#xD;
&#xD;
          -  Anti-neoplastic treatment given in the 2 weeks prior to apheresis, with the exception&#xD;
             of intrathecal chemotherapy.&#xD;
&#xD;
          -  Active immunosuppressive therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Amos Toren, MD,Phd</last_name>
    <phone>03-5302934</phone>
    <email>amos.toren@sheba.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elad Jacoby, MD</last_name>
    <phone>03-5302934</phone>
    <email>elad.jacoby@sheba.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chaim Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diana Bar</last_name>
      <phone>+972-3-5303699</phone>
      <email>Diana.Chigalayev@sheba.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Elad Jacoby, MD</last_name>
      <phone>+972-3-5302934</phone>
      <email>elad.jacoby@sheba.health.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Itzhaki O, Jacoby E, Nissani A, Levi M, Nagler A, Kubi A, Brezinger K, Brayer H, Zeltzer LA, Rozenbaum M, Vernitsky H, Markel G, Toren A, Avigdor A, Schachter J, Besser MJ. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients. J Immunother Cancer. 2020 Mar;8(1). pii: e000148. doi: 10.1136/jitc-2019-000148.</citation>
    <PMID>32152221</PMID>
  </reference>
  <reference>
    <citation>Fried S, Avigdor A, Bielorai B, Meir A, Besser MJ, Schachter J, Shimoni A, Nagler A, Toren A, Jacoby E. Early and late hematologic toxicity following CD19 CAR-T cells. Bone Marrow Transplant. 2019 Oct;54(10):1643-1650. doi: 10.1038/s41409-019-0487-3. Epub 2019 Feb 26.</citation>
    <PMID>30809033</PMID>
  </reference>
  <results_reference>
    <citation>Jacoby E, Bielorai B, Avigdor A, Itzhaki O, Hutt D, Nussboim V, Meir A, Kubi A, Levy M, Zikich D, Zeltzer LA, Brezinger K, Schachter J, Nagler A, Besser MJ, Toren A. Locally produced CD19 CAR T cells leading to clinical remissions in medullary and extramedullary relapsed acute lymphoblastic leukemia. Am J Hematol. 2018 Dec;93(12):1485-1492. doi: 10.1002/ajh.25274. Epub 2018 Sep 26.</citation>
    <PMID>30187944</PMID>
  </results_reference>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>May 9, 2016</study_first_submitted>
  <study_first_submitted_qc>May 12, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 13, 2016</study_first_posted>
  <last_update_submitted>November 1, 2020</last_update_submitted>
  <last_update_submitted_qc>November 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

